Murthy SB, Biffi A, Falcone GJ, et al. - Researchers conducted this multicenter cohort to explore the connection between antiplatelet therapy after intracerebral hemorrhage (ICH) and functional outcomes. Data were meta-analyzed from the Massachusetts General Hospital ICH registry (n = 1,854), the Virtual International Stroke Trials Archive database (n = 762), and the Yale stroke registry (n = 185). In total, 2,801 ICH patients were included, of whom 288 were started on antiplatelet medications after ICH. Data reported that median times to antiplatelet therapy ranged from 7 to 39 days. According to findings, antiplatelet therapy after ICH seemed safe and was not linked to all-cause mortality or functional outcome, regardless of the location of hematoma. To determine the effects and harms of antiplatelet therapy after ICH, randomized clinical trials are required.